Table 3 Proportions of published preprints in total and according to prevention type.
Published within 12 months n/N (%) | Median months until publication (range) | Median impact factor of journal where preprint was published (range) | |
|---|---|---|---|
Total | 161/329 (48.9%) | 5.3 (− 0.1*–11.3) | 3.2 (0.2–74.7) |
COVID-19 | 116/242 (47.9%) | 4.7 (− 0.1*–11.3) | 3.2 (0.2–74.7) |
Non-COVID-19 | 45/87 (51.7%) | 7.0 (1.3–11.3) | 3.4 (0.67–59.1) |
Prevention type | |||
Screening | 58/152 (38.2%) | 5.9 (− 0.1*–11.3) | 3.6 (0.2–53.4) |
Immunization | 31/66 (47.0%) | 4.7 (1.0–10.8) | 3.6 (0.8–59.1) |
Chemoprevention | 14/16 (87.5%) | 6.6 (0.3–10.6) | 3.2 (1.7–74.7) |
Counseling | 2/2 (100%) | 4.7 (4.2–5.3) | 3.8 (2.1–5.6) |
Other primary prevention | 54/90 (60.0%) | 4.7 (0.2–10.8) | 2.9 (0.5–21.6) |
Other secondary prevention | 2/3 (66.7%) | 5.1 (5.0–5.2) | 7.8 (5.4–10.2) |
